Enhancement of antitumor immunity by prolonging antigen presentation on dendritic cells
- 1 February 2002
- journal article
- research article
- Published by Springer Nature in Nature Biotechnology
- Vol. 20 (2) , 149-154
- https://doi.org/10.1038/nbt0202-149
Abstract
Vaccination with dendritic cells (DCs) pulsed with antigenic peptides derived from various tumor antigens has great, but as yet significantly unrealized, potential in cancer treatment. Here, we describe a strategy for prolonged presentation of an MHC class I–restricted self-peptide on DCs through linkage of it to a cell penetrating peptide (CPP). DCs loaded with a peptide derived from tyrosinase-related protein 2 (TRP2) covalently linked to a CPP1 sequence retained full capacity to stimulate T cells for at least 24 h, completely protected immunized mice from subsequent tumor challenge, and significantly inhibited lung metastases in a 3-day tumor model. DCs pulsed with TRP2 alone failed to provide any of these protections. In addition, we demonstrate that both CD4+ and CD8+ T cells were required for potent antitumor immunity. This CPP-based approach may be generally applicable to enhance the efficacy of DC-based peptide vaccines against cancer and other diseases.Keywords
This publication has 43 references indexed in Scilit:
- Immunization with a tumor-associated CTL epitope plus a tumor-related or unrelated Th1 helper peptide elicits protective CTL immunityEuropean Journal of Immunology, 2001
- In Vivo Protein Transduction: Delivery of a Biologically Active Protein into the MouseScience, 1999
- Genetic engineering of proteins with cell membrane permeabilityNature Biotechnology, 1998
- Identification of Tyrosinase-related Protein 2 as a Tumor Rejection Antigen for the B16 MelanomaThe Journal of Experimental Medicine, 1997
- Maturation Stages of Mouse Dendritic Cells in Growth Factor–dependent Long-Term CulturesThe Journal of Experimental Medicine, 1997
- Human tumor antigens recognized by T lymphocytes.The Journal of Experimental Medicine, 1996
- Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity.The Journal of Experimental Medicine, 1996
- Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo.The Journal of Experimental Medicine, 1996
- Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity.The Journal of Experimental Medicine, 1996
- Cellular uptake of the tat protein from human immunodeficiency virusCell, 1988